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ABSTRACT Enteropathogenic Escherichia coli (EPEC) is a leading cause of severe in-
testinal disease and infant mortality in developing countries. Virulence is mediated
by a type three secretion system (T3SS), causing the hallmark attaching and effacing
(AE) lesions and actin-rich pedestal formation beneath the infecting bacteria on the
apical surface of enterocytes. EPEC is a human-speciﬁc pathogen whose pathogene-
sis cannot be studied in animal models. We therefore established an EPEC infection
model in human gut xenografts in SCID mice and used it to study the role of T3SS
in the pathogenesis of the disease. Following EPEC O127:H6 strain E2348/69 infec-
tion, T3SS-dependent AE lesions and pedestals were demonstrated in all infected
xenografts. We report here the development of T3SS-dependent intestinal throm-
botic microangiopathy (iTMA) and ischemic enteritis in 50% of infected human gut
xenografts. Using species-speciﬁc CD31 immunostaining, we showed that iTMA was
limited to the larger human-mouse chimeric blood vessels, which are located be-
tween the muscularis mucosa and circular muscular layer of the human gut. These
blood vessels were massively invaded by bacteria, which adhered to and formed
pedestals on endothelial cells and aggregated with mouse neutrophils in the lumen.
We conclude that endothelial infection, iTMA, and ischemic enteritis might be cen-
tral mechanisms underlying severe EPEC-mediated disease.
KEYWORDS EPEC, T3SS, human gut xenograft, mouse model, thrombotic
microangiopathy
Enteropathogenic Escherichia coli (EPEC) is a leading cause of intestinal disease andinfant mortality in developing countries (1, 2). Due to their high morbidity and
mortality rates, EPEC infections represent an unmet challenge and a high research
priority (3). Virulence is mediated by a type three secretion system (T3SS), causing the
hallmark attaching and effacing (AE) lesions and actin-rich pedestal formation beneath
the infecting bacteria on the apical surface of the epithelial cells lining the gut. EPEC is
a human-speciﬁc pathogen, and despite impressive advances in our understanding of
EPEC pathogenesis at the cellular and genetic levels, the pathophysiology of the
resultant diarrhea and mortality remain unknown. Most of this advancing research has
been carried out on in vitromodel systems. However, the interplay of in vivo factors that
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result in diarrhea and neonatal mortality is very complex, and in vitro experiments yield
only limited results (4). Moreover, the relevance of elucidating EPEC virulence mecha-
nisms and their function during human infection can be validated only through clinical
studies in human infants (5). We have therefore set as our ﬁrst aim the establishment
of an EPEC infection model using human gut xenografts in SCID mice. We selected
prototypic EPEC strain E2348/69 O127:H6, which was originally isolated from an out-
break of infant diarrhea and thereafter has been used in human experimental infection
studies (6, 7). We report here the establishment of a model of EPEC infection in the
pediatric human gut which recapitulates the hallmark AE lesions and pedestal forma-
tion. Moreover, infection was also associated with manifestations of disease and
pathological changes that might have been overlooked in clinical cases. A better
understanding of the pathophysiology of EPEC infection in the pediatric human gut
might lead to the development of improved therapeutic approaches to this serious
disease.
RESULTS
In vitro system validation. T3SS activity in EPEC wild-type (WT) organisms and a
lack of activity in the ΔescVmutant were veriﬁed in vitro. While localized adherence and
microcolonies were formed by both strains (see Fig. S1 and S2 in the supplemental
material), pedestals of polymerized actin were visible only under EPEC WT bacteria
infecting EPH4 cells (Fig. S1).
Attaching and effacing lesions, pedestal formation, and inﬂammation in in-
fected human gut xenografts. The mean incubation period observed following
experimental challenge studies in humans was8 h, and this was therefore selected as
an endpoint in the present study. The challenge dose used in human studies was 1010
CFU; this was reduced to 107 CFU to accommodate the smaller size of the human
pediatric gut model system (6, 7). Next, the EPEC infection model system was optimized
to achieve colonization of the mucosal epithelial cells showing the typical attaching
and effacing (AE) lesions and pedestal formation 8 h after intraluminal injection of107
CFU (Fig. 1A to E). Consistent with our in vitro observation, the ΔescV mutant strain
formed microcolonies locally adherent to the microvilli on the apical membrane of
enterocytes (Fig. 1F) but was unable to form AE lesions and pedestals. Furthermore, our
experimental system clearly demonstrates that bacteria associated with AE lesions
accounted for only a minor fraction of the total number of intestinal EPEC bacteria.
The formation of AE lesions in the intact tissue within 8 h after infection was very
infrequent. We could detect it in only a few percent of the tested sections of a given
infected transplant (1 to 5%). Similarly, duodenal biopsy specimens obtained from
diarrheic adult volunteers 24 h after experimental EPEC infection appeared histologi-
cally normal, and no bacteria were detected (7). Therefore, effacing and the loss of gut
epithelial microvilli are unlikely to be the key mechanisms of diarrhea observed in
human patients. We concluded that EPEC infection of the human gut xenograft model
system recapitulated the characteristic virulence mechanisms and pathological
lesions previously reported in vitro and in vivo. Moreover, using quantitative PCR
(qPCR) analysis of whole human gut xenografts, we showed increased relative
expression of human (Fig. 2A) and mouse (Fig. 2B) cytokines, chemokines, and
NF-kappa-B-dependent genes 8 h after infection with the EPEC WT or ΔescV mutant,
with no signiﬁcant difference existing between the two strains. We concluded that
global gut inﬂammation was neither dependent on nor modulated by the T3SS.
Inﬂammation was most probably activated by microbe-associated molecular patterns
(MAMPs), such as lipopolysaccharide, lipoproteins, and ﬂagellin, as previously reported
from studies using the same model system (8, 9). Inﬂammation was not associated with
leukocyte recruitment into the mucosal tissues or lumen of infected gut xenografts.
These results correlate with those of experimental human infection studies demon-
strating signs of gut disease and systemic immune response (anti-O127 antibodies)
following oral challenge with EPEC O127:H6 strain E2348/69 and isogenic T3SS mutants
Nissim-Eliraz et al. Infection and Immunity
November 2017 Volume 85 Issue 11 e00558-17 iai.asm.org 2
(6, 7). However, on the basis of analysis of gut biopsy and fecal specimens, these
changes were not associated with leukocyte recruitment or tissue damage.
T3SS-dependent ischemic enteritis and microvascular thrombosis in infected
human gut xenografts. Histopathological analysis of the human gut xenografts was
performed 8 h after challenge with EPEC WT and ΔescV mutant organisms. Extensive
lesions were observed in approximately 50% of infected xenografts (Fig. 3), whereas
tightly adhering bacteria and AE lesions were visible in all infected xenografts. Patho-
logical lesions in xenografts infected with the EPEC wild-type strain were characterized
by well-demarcated areas of severe villous congestion (Fig. 3A and B) in association
with epithelial sloughing and intact lamina propria, while villous outlines were well
maintained (Fig. 3C to E, black arrows). The detachment of sheets of epithelial cells
together from the villi is a known characteristic of acute gut ischemia (10). None of the
xenografts infected with the ΔescV mutant organisms demonstrated the above-
described pathological lesions, as indicated by the histological score (Fig. 3F). Both
EPEC WT (Fig. 4A and B) and ΔescV mutant (Fig. 4C) organisms were visible in the
submucosal venous blood vessels, and systemic dissemination was conﬁrmed by
FIG 1 Attaching and effacing lesions and pedestal formation in EPEC-infected human gut xenografts. The interaction of EPEC O127 wild-type strain E2348/69
(A to E) and an isogenic ΔescVmutant strain (F) with human intestinal mucosa is shown. Foci of intimately adherent O127-positive bacteria were observed using
H&E staining (A, black arrows), immunostaining (B), GFP-expressing bacteria (C and D, white arrows), and transmission electron microscopy (TEM) (E, white
arrow). Pedestal formation under adherent bacteria and effacement of the brush border were demonstrated using confocal microscopy (showing a single
Z-stack) (D, yellow arrow) and TEM (E, yellow arrows). Colonies of the T3SS-defective ΔescV mutant strain clustered on the brush border but were unable to
form tight adhesion and effacement of the brush border (F, black arrows). Representative images of formalin-ﬁxed parafﬁn-embedded H&E-stained sections (A
and F) and ﬂuorescence staining of cryosections using DAPI (B to D, blue) and phalloidin (B to D, red) are shown. Bars, 50 m (A), 10 m (B), 1,000 nm (E), 200
nm (E, inset), and 20 m (F). Magniﬁcation, 63 (C and D).
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spleen cultures, with similar total counts being obtained for both strains (Fig. 4D).
However, following EPEC WT infection, the submucosal blood vessels were also heavily
congested with erythrocytes (RBCs) and neutrophils, forming large aggregates of
neutrophils and bacteria (Fig. 4E and F and S3). The adherence of both EPEC WT (Fig.
4E and F) and ΔescV mutant (Fig. 4C) organisms to endothelial cells lining the blood
vessels was clearly visible; however, actin pedestal formation was visible only under WT
bacteria (Fig. 4F and S3). The above-described pathological changes elicited by EPEC
WT organisms were consistently associated with microvasculature thrombosis (Fig. 5),
leading to ischemic injury and necrosis of the villous epithelium with viable crypts.
Histologically, the thrombi were limited to submucosal venous blood vessels located
between the muscularis mucosa and circular muscles (Fig. 5A) and were constructed of
ﬁbrin and entrapped neutrophils and RBCs (Fig. 5B to D). Moreover, the presence of
FIG 2 Markers of inﬂammation in EPEC-infected human gut xenografts. Elevated levels of expression of inﬂammatory markers in human gut
xenografts were detected 8 h after infection with EPEC O127 wild-type strain E2348/69 and isogenic mutant strain ΔescV. Species-speciﬁc
quantitative real-time RT-PCR was used to measure the relative levels of expression of human (A) and mouse (B) cytokines, chemokines, and
NF-kappa-B dependent genes in whole xenograft tissues. Expression levels were normalized against the levels for human 2-microglobulin (B2M)
or mouse -actin (Actb) mRNA and calculated relative to the expression levels for PBS-treated control xenografts using the 2ΔΔCT method. Data
are presented as ranges, and horizontal bars represent the medians. The differences between WT strain- and escV mutant-infected xenografts
were not statistically signiﬁcant. IL-8, IL-10, IL-1, and IL-6, interleukins 8, 10, 1, and 6, respectively; iNOS, inducible nitric oxide synthase; TNF-,
tumor necrosis factor alpha; KC, keratinocyte-derived chemokine.
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submucosal thrombi was in perfect correlation with the high score for ischemic villous
epithelial damage and congestion (histological score  4).
We concluded that intestinal thrombotic microangiopathy (iTMA)-driven ischemic
enteritis was T3SS dependent and might have been mediated by unknown perturba-
tions of endothelial cell functions and the aggregation of blood neutrophils and
bacteria.
Thrombosis is limited to submucosal human-mouse chimeric blood vessels.
The survival and normal development of the human fetal gut transplants are depen-
dent on a blood supply from the mouse host. The extent and connectivity of the mouse
and human vascular beds in the mature gut xenografts are unknown. Using species-
speciﬁc anti-CD31 staining, we show here that the villous capillary networks were of
human origin only (Fig. S4), while in the crypt zone we demonstrated two separate
capillary networks of human and mouse origin (Fig. S5). The larger blood vessels in the
submucosa were mostly of mouse origin; moreover, in this region we could demon-
strate blood vessels lined by a mosaic of human and mouse endothelial cells (Fig. 6).
Endothelial tightly adherent bacteria on actin pedestals, neutrophil aggregates (Fig. 4
and S3), and thrombosis (Fig. 5) were visible only in these human-mouse mosaic venous
blood vessels, which were exclusively present in the submucosa. Taken together, these
results suggest that it is likely that the development of thrombosis is linked to the
formation of actin pedestals in the associated endothelium of the human-mouse
mosaic blood vessels.
DISCUSSION
T3SS is considered the core virulence mechanism of EPEC, and AE lesions are the
hallmark lesions associated with gut colonization and disease. There is general agree-
ment among ﬁeld experts that the destruction of microvilli by organisms causing AE
lesions is the mechanism that underlies enteric disease and diarrhea (5). On the basis
FIG 3 Ischemic enteritis in EPEC-infected human gut xenografts. Foci of ischemic enteritis in a human gut xenograft 8 h after infection with EPEC O127 strain
E2348/69 bacteria are shown. Severe villous congestion is visible in a well-demarcated affected area (A, arrows), while the adjacent mucosa is not affected (B,
arrow). Sheets of mucosal epithelial cells are sloughing and detaching (C to E, black arrows), leaving behind denuded outlines of congested villi (E, red arrows).
(A to E) Representative images of formalin-ﬁxed parafﬁn-embedded H&E-stained sections. (F) The scatter plot presents the histopathological scores for infected
xenografts. Each data point represents a single xenograft. Mean scores (horizontal bars) were compared by an unpaired t test using GraphPad Prism (version
6) software (GraphPad Software, Inc.). A P value of 0.05 or less was considered signiﬁcant. Bars, 500 m (A and B), 100 m (C), and 50 m (D and E).
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of our observations in human gut xenografts and previously published human exper-
imental infections (6, 7), AE lesions seem to be rare and are unlikely the mechanism of
severe diarrhea and mortality associated with EPEC infection in infants (3). For many
years EPEC has been considered a prototypic gut pathogen colonizing the mucosal
surface. We show here that EPEC is able to traverse the mucosal barrier (known to be
deranged by EPEC infection) and that the interaction of EPEC with vascular endothelial
cells and blood neutrophils leads to thrombosis, congestion, and ischemic enteritis. Our
results suggest that effector proteins introduced by T3SS into vascular endothelial cells
might be the trigger of blood coagulation and thrombosis. Endothelial damage and
altered expression of surface proteins are known to trigger blood coagulation, clotting,
and thrombosis (11). To date, the effect of EPEC infection on human endothelial cells
has not been studied and requires further consideration in future research. Interest-
ingly, thrombotic microangiopathy of small blood vessels in the gut of infants dying of
EPEC infection was described in older papers (12, 13). These lesions might have been
overlooked and may contribute to the high rates of infant mortality associated with
EPEC infection still prevalent in developing countries.
E. coli is known to cause intestinal thrombotic microangiopathy (iTMA) and hemor-
rhagic enteritis. Pathogenesis is most commonly attributed to the AB5 Shiga toxins Stx1
and Stx2 and the subtilase cytotoxin (SubAB) (14–16). We suggest here that although
EPEC strains are not known to express these toxins (17), iTMA might be caused by an
alternative mechanism which is T3SS dependent. One such mechanism could be the
interaction of EPEC bacteria with host vascular endothelial cells. A second mechanism
FIG 4 Submucosal vascular bacterial invasion and lesions. Local and systemic invasion of EPEC bacteria following infection of human gut xenografts is shown.
(A to C) Both EPEC WT (black arrows in panel A and the magniﬁed view in panel B) and ΔescV mutant (C) bacteria are visible in submucosal blood vessels. (D)
Spleen tissue culture yielded similar bacterial cultures 8 h after challenge. (E and F) Only WT bacteria were associated with large aggregates of mouse
neutrophils in the infected blood vessels (white arrows). Endothelial adherence of escV mutant (C) and WT (E and F, red arrows) bacteria was clearly visible;
however, actin pedestals (F and inset in panel F, white arrows) were visible only under WT bacteria adhering to endothelial cells lining the blood vessels.
Representative images of formalin-ﬁxed parafﬁn-embedded H&E-stained sections (A to C) and of cryosections that included mCherry-expressing bacteria (E and
F, red) and that were stained with DAPI (E and F, blue) and phalloidin (E and F, green) are shown. Bars, 100 m (A), 50 m (B), and 20 m (C, E, and F). See
also Fig. S3 in the supplemental material.
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might be through interactions with blood neutrophils. We previously demonstrated a
link between the activation of neutrophils by E. coli bacteria and the release of
neutrophil extracellular traps (NETs) via a process called NETosis (18). This innate
immune response is an effective bacterial clearance mechanism that involves the
formation of an intravascular bactericidal net. NETosis has also been proposed to be a
mechanism contributing to pathological microvascular thrombosis under septic disease
conditions (19). However, although aggregates of mouse neutrophils and EPEC organ-
isms were rampant in the gut microvasculature undergoing thrombosis, we were
unable to demonstrate NETosis in this study.
In the model system used in the present study, transplants of human fetal gut
develop into mature pediatric gut. We show here that EPEC infection of the pediatric
human gut model can lead to severe pathological changes which are not explained by
AE lesions and pedestal formation on enterocytes. The same EPEC strain used in this
study was recently used to infect wild-type and immune-deﬁcient neonatal and young
mice. Interestingly, although the infecting organisms were able to produce typical AE
lesions and pedestals in the neonatal mouse gut, clinical and pathological changes
FIG 5 Intestinal thrombotic microangiopathy (iTMA). The thrombosis of submucosal blood vessels in human gut xenografts infected with EPEC O127 strain
E2348/69 bacteria is shown. Multiple thrombi were visible in venous blood vessels between the muscularis mucosa and circular muscles of the human gut
xenograft 8 h after infection with 107 CFU. (A and C) Vascular thrombosis was associated with severe villous congestion and ischemic necrosis of the mucosal
epithelium, while the crypts were spared. Thrombi are visible in the boxed areas (A and C, arrows), which are better visible under the larger magniﬁcation in
panels B and D. Thrombi consist of ﬁbrin ﬁbers (D, black arrow) entrapping numerous neutrophils (B and D, white arrows) and RBCs (B and D, yellow arrows).
Representative images of formalin-ﬁxed, parafﬁn-embedded, H&E-stained (A and B) and Masson’s trichrome-stained (C and D) sections are shown. Bars, 100 m
(A), 50 m (B and D), and 20 m (C).
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were not observed (20). It is unlikely that differences in intestinal microbiota are
responsible for the difference observed between the two model systems. It is more
likely that the difference reﬂects fundamental differences in the molecular mechanisms
of the human and mouse gut. Thus, the development of the human fetal gut into the
pediatric gut in SCID host mice is a unique model system that enables us to unveil the
pathogenesis and disease mechanisms of human-speciﬁc enteropathogens. Our model
was found to be highly reproducible and speciﬁc in its ability to recapitulate natural
infections by enteric pathogens like enterohemorrhagic E. coli (EHEC) O157:H7 (21) and
the probable zoonotic pathogen Mycobacterium avium subsp. paratuberculosis (22). In
the current study, we expanded our validation to EPEC. It is noteworthy that iTMA and
ischemic changes have also been described in the neonatal gut disease necrotizing
enterocolitis (NEC), which affects premature infants. However, in NEC, iTMA was found
in submucosal arterioles and led to coagulative necrosis of the mucosal epithelium (23,
24), while we describe here iTMA of the submucosal venules and ischemic necrosis of
the villous epithelium, with iTMA sparing the crypts. Recent work has implicated
uropathogenic E. coli (UPEC) colonization of the immature neonatal gut to be a
signiﬁcant risk factor for the development of NEC and subsequent mortality (25). The
cause of NEC is not clear, and there is no speciﬁc test for early identiﬁcation. The current
FIG 6 Submucosal human-mouse chimeric blood vessels. Submucosal venous blood vessels in human gut xenografts are comprised of anastomosing human
and murine endothelial cells. Representative images of formalin-ﬁxed, parafﬁn-embedded sections stained with murine anti-CD31 (muCD31) (A, green) and
human anti-CD31 (huCD31) (B, red) ﬂuorescent antibodies and DAPI (C and D, blue). The boxed area in panel C is enlarged for better visualization of overlapping
human (D, red arrows) and murine (D, green arrows) endothelial cells lining the blood vessels. Bars, 20 m (A to C) and 10 m (D).
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diagnostic tests, which entail biochemical and imaging techniques, are not sufﬁciently
speciﬁc, nor are they sensitive enough (26). Moreover, progress in NEC research is
hampered by the lack of an appropriate animal model. In conclusion, the human gut
xenograft model offers a unique system to study human-speciﬁc gut pathology,
including coagulopathies associated with colonization by strains of E. coli, as shown in
this report.
MATERIALS AND METHODS
SCID mouse human intestinal xenotransplant models. C.B-17/IcrHsd-Prkdcscid (abbreviated SCID)
mice were purchased from Harlan Biotech Israel (Rehovot, Israel). All mice were housed in a pathogen-
free facility in individually ventilated cages (IVC) and given autoclaved food and water.
Human fetal small bowel (gestational age, 12 to 18 weeks) was implanted subcutaneously on the
dorsum of the mouse as described previously (21, 22, 27). All surgical procedures were performed in an
aseptic working environment in a laminar-ﬂow HEPA-ﬁltered hood with isoﬂurane inhalation anesthesia
(1.5 to 2% [vol/vol] isoﬂurane in O2). Before surgery, carprofen (5 mg/kg of body weight; Rimadyl; Pﬁzer
Animal Health) was administered subcutaneously. The surgical area was shaved and depilated (with Nair
hair removal cream), and the skin was scrubbed and disinfected with Betadine and 70% (vol/vol) ethanol.
After surgery the mice were provided with enroﬂoxacin-medicated water (Bayer Animal HealthCare
AG) for 7 days and were closely monitored once a day for behavior, reactivity, appearance, and
defecation. The grafts developed in situ for 12 to 16 weeks prior to manipulation.
This study was carried out in strict accordance with the recommendations for the care and use of
laboratory animals of the National Institutes of Health. All procedures including animal studies were
conducted following the guidelines for the care and use of laboratory animals of the Israel Ministry of
Health and in accordance with Israeli law. The protocol was approved by the Animal Care and Use
Committee (IACUC) of the Hebrew University of Jerusalem. Institutional review board (IRB) and IACUC
approvals were obtained prospectively (Ethics Committee for Animal Experimentation, Hebrew Univer-
sity of Jerusalem [approval MD-11-12692-4] and the Helsinki Committee of the Hadassah University
Hospital [approval 81-23/04/04]). Women undergoing legal terminations of pregnancy gave written,
informed consent for the use of fetal tissue in this study.
Cells, bacteria, and plasmids. EPEC serotype O127:H6 wild-type (WT) strain E2348/69 (28) and its
ΔescV mutant (the escV deletion caused inactivation of the T3SS) (29) were used in this study. Plasmid
pSA11 carrying lacL and the green ﬂuorescent protein (GFP) gene (gfp) or the mCherry gene (cherry) gene
under the regulation of the tac promoter was introduced into the indicated strain, and GFP or mCherry
expression was achieved by isopropyl--D-1-thiogalactopyranoside (IPTG; Sigma, Israel) (30).
Bacteria were grown in Luria-Bertani (LB) broth at 27°C. For in vivo challenge studies, cultures were
diluted to 107 CFU in 100 l culture medium and injected into the lumen of the human gut xenografts.
To enable ﬂuorescence visualization of the infecting bacteria, 100 l of 10 mM IPTG solution in
phosphate-buffered saline (PBS) was injected into the lumen of the infected xenografts1 h before mice
were sacriﬁced for tissue harvesting. For enumeration of the bacteria in spleen, the organ was homog-
enized in 1 ml of PBS. Serial dilutions of the homogenates were plated onto LB agar, and the number of
CFU was determined after overnight incubation at 37°C. The detection limit of the CFU assay was 102
CFU per spleen.
In vitro EPEC infection of mammary epithelial cells. EPH4 murine mammary epithelial cells (kindly
donated by B. Aroeti, Hebrew University) were cultured in Dulbecco’s modiﬁed Eagle medium (DMEM)
supplemented with 10% fetal calf serum (FCS) (Biological Industries) and 100 units/ml penicillin–0.1
mg/ml streptomycin (Pen-Strep; Biological Industries) at 37°C with 5% CO2. The EPEC WT strain and the
ΔescV mutant carrying a green ﬂuorescent protein (GFP) expression plasmid were used for in vitro
infection experiments. Cells were grown on 12-mm glass coverslips in 24-well plates (Nunc) overnight
and were then infected with the EPEC WT strain or the escV mutant at a multiplicity of infection of 1 for
3 h. At 2 h after infection, IPTG was added to the culture medium at a ﬁnal concentration of 0.1 mM. The
slides were then ﬁxed with 4% paraformaldehyde (PFA) and stained with phalloidin (Sigma) and
4=,6=-diamidino-2-phenylindole (DAPI; Sigma). Coverslips were then mounted in mounting medium
(Vectashield), and pictures were taken with an epiﬂuorescence microscopy system (Axio Imager M1;
Zeiss, Germany). Confocal images were acquired using a Leica Microsystems TCS SP2 laser-scanning
spectrum confocal system, and images were merged using Leica confocal software.
Histochemical analysis. Mice were killed 8 h after challenge, and xenograft tissues were removed
for histology, ﬂuorescence staining, electron microscopy, and total bacterial counts. Samples for histo-
logical analysis were ﬁxed in neutral buffered 4% PFA and embedded in parafﬁn, and sections were cut
at a thickness of 5 m and stained with hematoxylin and eosin (H&E) or Masson’s trichrome according
to standard procedures.
Fresh xenograft tissue for ﬂuorescence staining was ﬁxed in 2.5% PFA overnight at room tempera-
ture, incubated with 15% (wt/vol) sucrose for 12 h at 4°C, and frozen in Tissue-Tek embedding medium
(Electron Microscopy Sciences, Hatﬁeld, PA). Serial 10-m cryosections were stained with phalloidin
(Sigma) and DAPI (Sigma).
Staining of an EPEC O-antigen type strain was performed using rabbit anti-O127 (Statens Serum
Institute, Denmark), and goat anti-rabbit IgG (catalog number ASF488; Invitrogen) was used as the
secondary antibody. Endothelial cells were stained with rabbit anti-human CD31 (catalog number
EPR3094; Abcam) and rat anti-murine CD31 (clone SZ31; Dianova, Hamburg, Germany). Donkey anti-
rabbit immunoglobulin conjugated with Alexa Fluor 546 (catalog number A10040) and donkey anti-rat
Enteropathogenic E. coli Infection in the Human Gut Infection and Immunity
November 2017 Volume 85 Issue 11 e00558-17 iai.asm.org 9
immunoglobulin conjugated with Alexa Fluor 488 (catalog number A21208) (both from Life Technolo-
gies) were used as secondary antibodies.
Sections were mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA)
and imaged with an Axio Imager M1 upright ﬂuorescence microscope (Zeiss, Germany). Confocal images
were acquired using a Leica Microsystems TCS SP2 laser-scanning spectrum confocal system, and images
were merged using Leica confocal software.
TEM. Samples for transmission electron microscopy (TEM) were ﬁxed with a mixture of 2.5%
glutaraldehyde in 0.1 M phosphate buffer, pH 7.2, for 2 h and then washed with 0.1 M phosphate buffer.
After osmiﬁcation, dehydration, and embedding (Epon), the tissue was sectioned using an LKB-Ultrotome
8800 III ultramicrotome and observed with a Tecnai 12 TEM (Phillips, Eindhoven, The Netherlands)
equipped with a MegaView II charge-coupled-device camera and AnalySIS (version 3.0) software.
Intestinal villous injury scoring. Scoring of histopathology was done by an individual blind to the
treatment using a validated scoring system. Three independent parameters were measured: villous
ischemic damage (scores, 0 to 3 for no, slight, moderate, and severe damage, respectively), cellular
inﬁltration (scores, 0 to 3 for no, slight, moderate, and perfuse inﬁltration, respectively), and congestion
and hemorrhage (scores, 0 to 3 for none, slight, moderate, and severe congestion and hemorrhage,
respectively).
Quantitative RT-PCR. Total RNA was isolated from gut xenograft tissue using a GenElute mammalian
total RNA miniprep kit (Sigma, Rehovot, Israel) combined with an on-column DNase I digestion set
(Sigma). Reverse transcription (RT) was performed using a qScript cDNA synthesis kit (Quanta Biosciences,
Gaithersburg, MD, USA), and cDNA was used for subsequent real-time PCRs. Quantitative real-time
RT-PCR was conducted on a StepOne Plus PCR instrument (Applied Biosystems) using Fast qPCR
Universal master mix (Kappa Biosystems, Boston, MA, USA). Species-speciﬁc primer pairs speciﬁc for the
target human and mouse genes used in this study were designed and are listed in Table S1 in the
supplemental material. To avoid any cross talk, primers were designed to amplify speciﬁcally human or
mouse transcripts. All reactions were performed in triplicate, and the gene expression levels for each
amplicon were calculated using the 2ΔΔCT threshold cycle (CT) method (31), and the levels were
normalized against those for human 2-microglobulin (B2M) or mouse -actin (Actb) mRNA. Melting
curve analysis was performed with each primer set to conﬁrm ampliﬁcation of a single product, and all
amplicons were sequenced to ensure reaction speciﬁcity (data not shown).
Statistical analysis. Parametric data (clinical scores) and nonparametric data (relative levels of
expression of genes and CFU counts) were calculated as the mean and median, respectively. For
comparison of parametric and nonparametric data, a t test and a nonparametric Mann-Whitney two-
independent-samples test, respectively, were applied using GraphPad Prism (version 6) software (Graph-
Pad Software, Inc.). A P value of 0.05 or less was considered signiﬁcant.
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